Phase I/II data for neoGAA in Pompe disease presented
Sanofi and its specialty care global business unit Sanofi Genzyme has presented data from NEO1, its Phase I/II clinical study evaluating the investigational novel enzyme replacement therapy neoGAA in 24 patients with late-onset Pompe disease.
Click on this link for more information.
